Article
Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology - 1 Feb 2008
Nakatani Masashi, Takehara Yuka, Sugino Hiromu, Matsumoto Mitsuru, Hashimoto Osamu, Hasegawa Yoshihisa, Murakami Tatsuya, Uezumi Akiyoshi, Takeda Shin'ichi, Noji Sumihare, Sunada Yoshihide, Tsuchida Kunihiro
Abstract excerpt
Myostatin is a potent negative regulator of skeletal muscle growth. Therefore, myostatin inhibition offers a novel therapeutic strategy for muscular dystrophy by restoring skeletal muscle mass and suppressing the progression of muscle degeneration. The known myostatin inhibitors include myostatin...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.